Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Patent
1997-08-27
2000-04-11
Housel, James C.
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
4241311, 4241301, 4242501, 4241841, 5303871, 5303881, 5303884, 530808, 514 2, 514898, A61K 39395, A61K 39095, A61K 3900, C07K 1600
Patent
active
060485272
ABSTRACT:
Novel bactericidal antibodies against Neisseria meningitidis serogroup B ("MenB") are disclosed. The antibodies either do not cross-react or minimally cross-react with host tissue polysialic acid and hence pose minimal risk of autoimmune activity. The antibodies are used to identify molecular mimetics of unique epitopes found on MenB or E. coli K1. Examples of such peptide mimetics are described that elicit serum antibody capable of activating complement-mediated bacteriolysis of MenB. Vaccine compositions containing such mimetics can be used to prevent MenB or E. coli K1 disease without the risk of evoking autoantibody.
REFERENCES:
patent: 4727136 (1988-02-01), Jennings et al.
patent: 4970070 (1990-11-01), Raff
patent: 5576002 (1996-11-01), Jennings et al.
patent: 5683699 (1997-11-01), Jennings et al.
Granoff et al. J. Immunol. 160: 5028-5036, 1998.
Kabat et al. J. Exp. Med. 164: 642-654, 1986.
Livingston et al. J. Biol. Chem. 263: 9443-9448, 1988.
Bitter-Suermann et al. Immunol. Res. 225-237, 1987.
Tome et al. Acta Pathol. Jpn. 43: 168-175, 1993.
Vaesen et al. Biol. Chem. Hoppe. Seyler 372: 451-453, 1991.
Klebert et al. Biol. Chem. Hoppe Seyler 374: 993-1000, 1993.
Pon et al. J. Exp. Med. 185: 1929-1938, Jun. 1997.
Baumann et al. Biochemistry 32: 4007-4013, 1993.
Sato et al. J. Biol. Chem. 270: 18923-18928, 1995.
FE Ashton et al. Mibrob. pathogenesis 6: 455-458 (Cited as reference A), 1989.
FE Ashton et al. In: Neisseria 1990, Achtman M (Ed.), Walter De Gruyter & Co., Berlin, pp. 187-191 (Cited as reference B), 1991.
K. Sukkonen et al. Mibrobial Pathogenesis 1: 101-105, 1986.
Lifely et al. Immunology 74: 490-496, 1991.
G Rougon et al. J. Cell Biol. 103: 2429-2437, 1986.
HV Raff et al. J. Infect. Dis. 157 (1): 118-126, 1988.
CM Hurpin et al. Hybridoma 11 (6): 677-687, 1992.
M Husmann et al. J. Histochem. Cytochem. 38: 209-215, 1990.
A Bartoloni et al. Vaccine 13 (5): 463-470, 1995.
C Moreno et al. J. Gen. Microbiol. 129: 2451-456, 1983.
AS Cross et al. J. Infect. Dis. 147 (1): 68-76, 1983.
M Leinonen et al. Infect. immun. 38 (3): 1203-1207, 1982.
M Frosch et al. PNAS 82: 1194-1198, 1985.
NA Gregson et al. Biochem. Soc. Transact. 13: 462, 1985.
Devi et al. In: Neisseria: Proc. Ninth Internat. Pathogenic Neisseria Conference FEMS Immunol. Med. Microbiol. Evans et al. (Ed.), S.C.C., England, pp. 427-429, 1994.
Devi et al. FEMS Immunol. Med. Microbiol. 14 (Jul.): 211-220, 1996.
Westerink et al., "Development and Characterization of an Anti-idiotype Antibody to the Capsular Polysaccharide of Neisseria Mengingitidis Serogroup C," Infection and Immunity 56(5):1120-1127 (1988).
Horwell, David C., "The `Peptoid` Approach to the Design of Non-Peptide, Small Molecule Agonist and Antagonists of Neuropeptides," TIBTech 13 (4):132-134 (1995).
Brisson et al., "Helical Epitope of the Group B Meningococcal .alpha.(2-8)-Linked Sialic Acid Polysaccharide," Biochemistry 31:4996-5004 (1992).
Dubois et al., "A Monoclonal Antibody Against Meningococcus Group B Polysaccharides Used to Immunocapture and Quantify Polysialylated NCAM in Tissues and Biological Fluids," Journal of Immunological Methods 181:125-135 (1995).
Frasch, Carl E., "Meningococcal Vaccines: Past, Present and Future," Meningococcal Disease 245-283 (1995).
Fusco et al., "Preclinical Evaluation of a Novel Group B Meningococcal Conjugate Vaccine that Elicits Bactericidal Activity in Both Mice and Nonhuman Primates," The Journal of Infectious Disease 175:364-372 (1997).
Granoff et al., "Antibody Responses to the Capsular Polysaccharide of Neisseria Menignitidis Serogroup B in Patients With Meningcoccal Disease," Clinical and Diagnostic Laboratory Immunology 2(5):574-582 (1995).
Hayrinen et al., "Antibodies to Polysialic Acid and its N-Propyl Derivative: Binding Properties and Interaction with Human Embryonal Brain Glycopeptides," The Journal Of Infectious Diseases 171:1481-1490 (1995).
Jennings, Harold J., "The Capsular Polysaccharide of Group B Neisseria Meningitidis as a Vehicle for Vaccine Development," Microbiol. Immunol. 10:151-165 (1989).
Jennings et al., "Induction of Meningococcal Group B Polysaccharide-Specific IgG Antibodies in Mice by Using an N-Propionylated B Polysaccharide-Tetanus Toxoid Conjugate Vaccine," The J. Of Immunology 137(5):1708-1713 (1986).
Jennings et al., "N-Polysialic Group B Meningococcal Polysaccharide Mimic a Unique Epitope on Group B Neisseria Meningitidis," J. Experimental Medicine 165:1207-1211 (1987).
Jennings et al., "Unique Intermolecular Bactericidal Epitope Involving the Homosialopolysaccharide Capsule on the Cell Surface of Group B Neisseria Meningitidis and Escherichia Coli K1," Journal of Immunology 142(10):3585-3591 (1989).
Jennings et al., "Immunochemistry of Groups A,B, and C Meningococcal Polysaccharide-Tetanus Toxoid Conjugates," The Journal of Immunology 127(3):1011-1018 (1981).
Lucas et al., "Functional Differences in Idiotypically Defined IgG1 Anti-Polysaccharide Antibodies Elicited by Vaccination with Haemophilus Influenzae Type B Polysaccharide-Protein Conjugates," The Journal of Immunology 154:4195-4202 (1995).
Mandrell et al., "Complement-Mediated Bactericidal Activity of Human Antibodies in Poly W .alpha.2.fwdarw.8 N-Acetylneuraminic Acid, the Capsular Polysaccharide of Neisseria Meningitidis Serogroup B," The Journal of Infectious Diseases 172:1279-1289 (1995).
Michon et al., "Conformational Differences Between Linear .alpha.(2.fwdarw.8)-Linked Homosialooligosaccharides and the Epitope of the Group B Meningococcal Polysaccharide," Biochemistry 26:8399-8405 (1987).
Poolman, Jan T., "Development of a Meningococcal Vaccine," Infectious Agents and Disease 4:13-28 (1995).
DataBase WPI., "Novel Strain of Neisseria Meningitidis Group Useful Produce Capsule Polysaccharide Protein Complex," Jan. 30, 1992.
Granoff Dan M.
Moe Gregory R.
Blackburn Robert P.
Children's Hospital Medical Center of Northern California
Chiron Corporation
Devi S.
Harbin Alisa A.
LandOfFree
Antibodies that define unique Meningococcal B epitopes and vacci does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibodies that define unique Meningococcal B epitopes and vacci, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibodies that define unique Meningococcal B epitopes and vacci will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1174513